Thermo Fisher Scientific Inc., a global leader in scientific research and innovation, has announced the enrollment of the first patient in its new PPD CorEvitas Obesity Registry. This observational, prospective registry is designed to generate real-world evidence on the long-term safety, effectiveness, and patient experience of obesity management therapies, including anti-obesity medications. By gathering data directly from both healthcare providers and patients, the registry will offer insights into treatment patterns, adherence, patient satisfaction, and clinical outcomes, including anthropometric measurements, across diverse care settings.
Health Technology Insights: OsteoCentric Technologies Appoints Matthew Collier to Board of Directors
Obesity is a complex, chronic condition influenced by genetic, environmental, and psychosocial factors. It is associated with significant comorbidities such as type 2 diabetes, cardiovascular disease, and certain cancers, while also impacting mobility, mental health, and overall quality of life. In the United States, over 100 million adults are affected by obesity, including more than 22 million with severe obesity. Globally, the economic burden of overweight and obesity is projected to reach three trillion dollars annually by 2030 and could rise to over eighteen trillion dollars by 2060.
Health Technology Insights: Samsung Biologics Acquires Human Genome Sciences from GSK
Leslie Harrold, M.D., vice president and global head of real-world science and strategy for PPD CorEvitas Clinical Registries at Thermo Fisher Scientific, stated that the CorEvitas Obesity Registry represents an important advancement in understanding how obesity treatments perform in real-world clinical practice. She emphasized that the insights from the registry will provide the healthcare community with meaningful data on treatment safety, effectiveness, and patient experience, ultimately helping to improve care for millions of individuals living with obesity.
The registry will collect comprehensive physician- and patient-reported outcomes to track disease progression, treatment response, and the challenges patients face throughout their care journey. The findings are intended to inform clinical practice, guide future research, and support the development of evidence-based strategies for managing obesity. This registry marks the fifteenth independent registry established under PPD™ CorEvitas™ Clinical Registries, which operates as part of the PPD clinical research division of Thermo Fisher Scientific.
CorEvitas Clinical Registries provide structured, regulatory-grade patient data across more than 500 investigator sites and include longitudinal data on over 100,000 patients. The independent registry model has been accepted by regulatory authorities for long-term post-authorization safety studies in multiple therapeutic areas, demonstrating its robustness and reliability for generating real-world evidence to support patient care and clinical decision-making.
Health Technology Insights: SCIENTURE Launches FDA-Approved High-Strength REZENOPY
To participate in our interviews, please write to our HealthTech Media Room at info@intentamplify.com
